Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mesoblast to begin US spine surgery trial

This article was originally published in Clinica

Executive Summary

Mesoblast is to initiate a US phase II trial of its allogeneic adult stem cells in minimally-invasive lumbar spinal fusion surgery. The 24-patient trial will compare two low doses of Mesoblast's product, NeoFuse, with autografting of patients' own hip bones – the gold-standard treatment for this disorder. Previous trials assessing NeoFuse's use in spinal fusion performed via more invasive surgery showed that the therapy can generate safe and robust fusion over a 12-month period, Melbourne, Australia-based Mesoblast said. The firm will follow this trial, if it is successful, with a phase III study to enable US approval of NeoFuse.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044070

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel